Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity IMAGION BIOSYSTEMS LIMITED ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director David LUDVIGSON Date of last notice 01 May 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 23 June 2020 No. of securities held prior to change i) 420,000 Shares ii) 50,000 Performance vested on 6 June 2020. iii) 75,000 Listed options (exercisable at $0.05 expiring on 26 November 2021) iv) 120,000 Listed options (exercisable at $0.03 expiring on 28th April 2023) Class i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights iii) Listed options (exercisable at $0.05 expiring on 26 November 2021) iv) Listed options (exercisable at $0.03 expiring on 28th April 2023) i) 50,000 Shares ii) Nil Performance Rights iii) Nil Listed options (exercisable at $0.05 expiring on 26 November 2021) iv) Nil Listed options (exercisable at $0.03 expiring on 28th April 2023) Number acquired + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Number disposed i) Nil Shares ii) 50,000 Performance Rights iii) Nil Listed options (exercisable at $0.05 expiring on 26 November 2021) iv) Nil Listed options (exercisable at $0.03 expiring on 28th April 2023) Value/Consideration i) Nil per Share ii) N/A Performance Rights iii) N/A Listed options (exercisable at $0.05 expiring on 26 November 2021) iv) N/A Listed options (exercisable at $0.03 expiring on 28th April 2023) Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change i) 470,000 Shares ii) 75,000 Listed options (exercisable at $0.05 expiring on 26 November 2021) iii) 120,000 Listed options (exercisable at $0.03 expiring on 28th April 2023) Nature of change Vesting of Performance Rights which were issued on 14 June 2018 under Company’s LTIP, as approved by Shareholders on 31 May 2018. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) Date of change N/A No. and class of securities to which interest related prior to change N/A N/A Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? No N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice If prior written clearance was provided, on what date was this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 N/A